The National Cancer Institute (NCI) awarded Georgetown University a $401,115 Project Grant under the Cancer Biology Research program (CFDA 93.396) to develop and validate a 3D bioengineered microfluidic platform for research on Ewing sarcoma bone metastasis. The platform, called 3D-BMP, aims to mimic the bone microenvironment to enable high-throughput genomic screening on the mechanisms driving Ewing sarcoma's propensity to metastasize to bone. The project will use this platform to perform a CRISPR dropout assay to identify candidate genes crucial for Ewing sarcoma's dissemination and survival in the bone. Validated targets will then be tested in in vivo models to confirm the biological relevance of the 3D-BMP platform. This award runs from July 2, 2024 to June 30, 2026 and will establish 3D-BMP as a model system for studying bone metastasis in Ewing sarcoma and potentially other cancers.